Evidence Hub

Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021

Long T, Lovey A, Sanborn L, Zhao Y, Bulman ZP, Lin YT, Chen L

Emerging infectious diseases, 2026

1 citation

Abstract

Carbapenem-resistant Enterobacterales (CRE) are a major global health threat with limited treatment options. Aztreonam/avibactam is a promising therapy against metallo-β-lactamase (MBL)-producing and other CRE, but emerging resistance threatens its effectiveness. Insertions in penicillin-binding protein 3 (PBP3), which are well described in Escherichia coli, are linked to reduced aztreonam/avibactam susceptibility but remain poorly characterized in Klebsiella pneumoniae. We report clinical K. pneumoniae carbapenemase-producing K. pneumoniae sequence type 11 isolates carrying a novel PBP3 YRIT insertion, conferring reduced susceptibility to aztreonam/avibactam and ceftazidime/avibactam. Functional and genetic studies suggest that the PBP3 insertion impairs β-lactam binding and, in combination with blaKPC-2 and other β-lactamases, contributes to reduced susceptibility. Those findings demonstrate the emergence of a PBP3 insertion in a high-risk K. pneumoniae clone, underscoring the expansion of this resistance mechanism and the critical need for genomic surveillance and novel therapeutics to identify and treat such infections.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free